Insight Molecular Diagnostics Inc. Common Stock logo

Insight Molecular Diagnostics Inc. Common Stock (IMDX) Q1 2025 Earnings

IMDX·Reported May 12, 2025·After market close

Insight Molecular Diagnostics Inc. Common Stock reported Q1 2025 revenue of $2.1M (+1114.8% YoY), beat analyst consensus of $126.8K by $2.0M. Diluted EPS came in at $-0.26 (+77.0% YoY), missed the $-0.24 consensus by $0.02.

Revenue
$2.1Mbeat by $2.0M
Consensus: $126.8K
Diluted EPS
$-0.26missed by $0.02
Consensus: $-0.24
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-25-069213

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Insight Molecular Diagnostics Inc. Common Stock's Q1 2025 earnings report.

Insight Molecular Diagnostics Inc. Common Stock (IMDX) reported Q1 2025 earnings on May 12, 2025 after market close.

Insight Molecular Diagnostics Inc. Common Stock reported revenue of $2.1M and diluted EPS of $-0.26 for Q1 2025.

Revenue beat the consensus estimate of $126.8K by $2.0M. EPS missed the consensus estimate of $-0.24 by $0.02.

Compared to the same quarter a year prior, revenue grew 1114.8% from $176.0K a year earlier and diluted EPS grew 77.0% from $-1.13.

You can read the 10-Q periodic report (0000950170-25-069213) directly on SEC EDGAR. The filing index links above go to sec.gov.